Tech stocks are bleeding, and healthcare is the tourniquet. On Friday, shares of AbbVie, Eli Lilly, and Johnson & Johnson all flirted with all-time highs. This wasn't a blip. It's a stampede.
The message from Wall Street is clear: the party in tech is winding down, and investors are nursing hangovers with the steady, boring embrace of biopharma. The sector that everyone ignored in 2024 is suddenly the belle of the ball.
From Growth to Guts
For the past two years, every conversation about where to park cash started and ended with the Magnificent Seven. AI this, cloud that. But the music is changing. Tech valuations got frothy, interest rates stayed stubborn, and regulators started circling. Suddenly, a company that makes pills looks a lot safer than one that makes chatbots.
AbbVie pulled in $56 billion in revenue last year. Eli Lilly's diabetes and obesity drugs are flying off shelves. Johnson & Johnson has enough divisions — pharmaceuticals, medical devices, consumer health — to weather any storm. These aren't flashy businesses. They're anchors.
"The rotation into healthcare isn't just defensive — it's offensive. These companies have pricing power, aging demographics, and pipelines that stretch a decade out."
The market is finally pricing that in. Year-to-date, the Health Care Select Sector SPDR Fund (XLV) is up 18%, outpacing the S&P 500's 12% gain. Meanwhile, the tech-heavy Nasdaq is flat.
AbbVie's Immune Boost
AbbVie, in particular, has surprised skeptics. When Humira, its $21 billion blockbuster, finally faced biosimilar competition in 2023, analysts predicted a slow bleed. Instead, the company launched Skyrizi and Rinvoq, two immunology drugs that are already picking up the slack. Combined sales for those two drugs hit $11 billion last year — and they're still growing at 20% clip.
That's not just defense. That's a counterpunch.
Eli Lilly: The Obesity King
Eli Lilly has become the poster child for the sector's resurgence. Its diabetes drug Mounjaro and its obesity counterpart Zepbound are generating $5 billion in quarterly sales. Demand is so high that the company can't make enough. It's building new factories, hiring thousands, and still can't keep up.
The obesity market is projected to hit $100 billion by 2030. Eli Lilly and Novo Nordisk are the only two players with approved drugs. That's a duopoly with a moat wide enough to swim a cruise ship through.
Johnson & Johnson's Steady Hand
Johnson & Johnson might be the least exciting of the three, but that's the point. After spinning off its consumer health division into Kenvue, J&J is now a pure-play pharma and medtech company. Its pipeline includes treatments for multiple myeloma, lung cancer, and depression. The company raised its dividend for the 62nd straight year. Boring? Sure. But try finding that kind of consistency in tech.
Why Now?
The rotation isn't random. Three forces are converging.
First, interest rates. The Fed has held rates above 5% for over a year. High rates punish growth stocks — like tech — because their future earnings are worth less today. Healthcare stocks, with their steady cash flows, become relatively more attractive.
Second, regulation. The Biden administration's antitrust push has hit Big Tech hard. Microsoft's Activision deal faced lawsuits. Google's search monopoly trial ended with a breakup threat. Amazon's pharmacy ambitions were slowed. Meanwhile, pharma companies face scrutiny too, but they've been playing defense for decades. They know the game.
Third, demographics. The oldest Baby Boomers are turning 80 this year. That's a lot of prescriptions, surgeries, and hospital visits. The healthcare sector has a demographic tailwind that won't fade for another two decades.
The Risks
Of course, it's not all rosy. Drug pricing reform is still a threat. Medicare negotiations under the Inflation Reduction Act could squeeze profits on the most expensive drugs. Abbott, Pfizer, and Merck all face patent cliffs in the next few years.
And there's the valuation question. Healthcare stocks aren't cheap anymore. The sector trades at 18 times forward earnings, above its five-year average of 16. But compared to tech, which trades at 28 times, it still looks like a bargain.
The Bottom Line
Investors are realizing that healthcare isn't just a defensive sector — it's a growth sector disguised as one. The companies that survived the pandemic, navigated patent cliffs, and battled regulators are leaner and meaner than ever.
AbbVie, Eli Lilly, and Johnson & Johnson aren't just hitting all-time highs. They're making a statement. Tech had its run. Now it's healthcare's turn.
Don't bet against the pills.
